期刊文献+

二甲双胍对2型糖尿病合并动脉粥样硬化患者血清基质金属蛋白酶2、IL-6、8的影响

The Effect of Metformin Treatment on Serum Matrix Metalloproteinase-2,IL-6 and 8 in Patient with T2DM and Atherosclerosis
下载PDF
导出
摘要 目的:探讨二甲双胍对2型糖尿病合并动脉粥样硬化患者基质金属蛋白酶2(Matrix metalloproteinase-2,MMP-2)及IL-6、8的影响。方法:51例2型糖尿病患者根据颈动脉内中膜厚度(IMT)及斑块分为动脉粥样硬化组(35例)和无动脉粥样硬化组(16例)。动脉粥样硬化组中又分为治疗组(20例,二甲双胍治疗24周)和未治疗组(15例)。随访24周,治疗前、后均检测生化及MMP-2、IL-6、8等指标。结果:(1)Spearman相关分析显示体重指数(BMI)和MMP-2和IL-6、8显著正相关(P<0.01)。(2)治疗前动脉粥样硬化组MMP-2和IL-6、8与无动脉粥样硬化组比较,显著升高(P<0.01),与无动脉粥样硬化组比较,TG显著高,而HDL-C显著降低(P<0.05)。(3)与治疗前比较,治疗组治疗24周后MMP-2和IL-6、8明显下降(P<0.01),TC、TG和低密度脂蛋白胆固醇(LDL-C)显著下降(P<0.01),HDL-C上升(P<0.01)。结论:2型糖尿病合并动脉粥样硬化患者MMP-2和IL-6、8明显升高。二甲双胍降低血糖、体重外,可以通过减低MMP-2和IL-6、8水平来发挥其抗动脉粥样硬化作用。 Objective:To investigate the effect of metformin on the MMP-2 and IL-6, 8 in patients with type 2 diabetes. Methods.. To recruit 51 T2DM patients with atherosclerosis. The patients were treated with metformin for 24 weeks without a change in previous medications. Levels of plasma lipids and MMP-2 and IL-6, 8 were measured. To compare the treatment effects between three groups after 24 weeks treatment. Results: After metformin for 24 weeks, MMP-2 and II.-6, 8, TC and TG were lower than before, HDL-C were increased. Conclusion.. Beneficial effects of metformin may be due to non-lipid actions, metformin can exert anti-atherosclerotic effect by reducing the expression of MMP-2 and IL-6,8.
出处 《医学理论与实践》 2013年第21期2806-2808,共3页 The Journal of Medical Theory and Practice
关键词 二甲双胍 基质金属蛋白酶2 白细胞介素6 白细胞介素8 2型糖尿病动脉粥样硬化 Metformin, Matrix metalloproteinase-2, IL-6, IL-8, Type 2 diabetes mellitus, Atherosclerosis
  • 相关文献

参考文献14

  • 1Ferranti SD,Rifai N. C- reactive protein and cardiovascular disease: a review of risk prediction and intervention[J]. Clin Chim Acta,2002,317:1-15.
  • 2Wang N,Tabas al. Interleukin 8 is induced by cholesterolloading of macrophages and expressed by macrophage foam cellsin human atheroma[J]. J Biol Chem, 1996,271 : 8837-8842.
  • 3Van Snick J. Interleukin-6 . an overview[J]. Annu Rev Immun-lo,1999,8:253-278.
  • 4Zeng B,Prasan A.Fung KC,et al. Elevated circulating levels ofmatrix metaIloproteinase-9 and-2 in patients with symptomaticcoronary artery disease[J]. Intern Med J,2005,35(6) :331-335.
  • 5Kissela BM, Khoury J,Kleindorfev D, et al. Epidemiology ofisehemie strokein Patients with diabetes : the greater Cinein-nati/Northen Kentueky Stroke Study[J]. Diabetes Care,2005,28(2):355-359.
  • 6Ross R. Atherosclerosis-aninflammatory disease[J]. N Engl JMed,1999,340(2):115.
  • 7Berg AH,Scherer PE. Adipose Tissue,Inflammation and Cardi-ovascular DiseaseG]. Circulation Research,2005,96 j 939.
  • 8Abilleira S,Bevan S,Markus HS. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclero- sis[J]. J reed Genet,2006,43(12) :897-901.
  • 9Loftus IM, Naylor AR, Goodall S. Increase matrix metallopro-teinase-2 activity in unstable carotid plaque. A potential role onacute plaque disruption[J]. Stroke, 2003,31(1) :40.
  • 10Galis ZS, Sukhova GK,et al. Macrophagefoam cells from ex-perimental atheroma constitutively produce matrix-degradingproteinases[J]. Proc Natl Acad Sci USA, 1995,92(1) :402.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部